AARTIPHARM Aarti Pharmalabs Q4 FY25 results (Jan–Mar 2025) and concall
Aarti Pharmalabs delivered a strong FY25 with significant growth in revenue, EBITDA, and PAT, driven by robust performance across all segments. The company is progressing with key capacity expansions in Xanthine and Atali, though the Atali project timeline has been adjusted. Sustainability efforts were recognized, and the company provided positive guidance for FY26, despite some short-term impacts on the Ganesh Polychem business.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 458 | 538 | 564 |
| EBITDA | 94 | 129 | 146 |
| Net profit | 55 | 74 | 88 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
